🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

On being a good doctor. The number of research publications don’t tell you how good a doctor is at being a doctor. Neither do the number of book chapters or grants. Or academic rank. It’s a different skill set. Good doctors have stellar clinical acumen & empathy. #MedTwitter

1/x Much awaited BMT CTN 1506 trial out in Journal of Clinical Oncology establishing gilteritinib as SOC post #alloBMT maintenance in #MRD +ve FLT3-ITD #AML pts in CR1; thanks to a global collaboration funded by Astellas Pharma US NIH NHLBI and National Cancer Institute to BMT CTN tweetorial👇 ascopubs.org/doi/pdf/10.120…

Timely piece on CLL survivorship by Stephen Opat and Pasquale Fedele Monash Health in the JCO ascopubs.org/doi/10.1200/JC…

Machine learning methods: a new study examining validation of the European LeukemiaNet 2022 criteria and genomic clusters in older adults with #acute_myeloid_leukemia. haematologica.org/article/view/h…

Congratulations Ross, Rory and Jacinta and well done ALLG for supporting this initiative. Great to have Ross on board in our trial unit Monash Health now

WEHI's Dr Sarah Diepstraten spoke with @10NewsFirstMelb about the novel combination of two cancer drugs that has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML). Watch the segment 👇

We’re hiring! Research Fellows 2025 at Monash Health: - Lymphoma / Cellular Therapies - Myeloid Diseases Come work with our fantastic team! Chyn C Jake Shortt Erica Wood Stephen Opat and many more Monash University School of Clinical Sciences careers.monashhealth.org/job/Clayton-20…

Come and join us at Monash Health in 2025 for an exciting journey and growth 📈

We (Monash Haematology team) are running for Monash Haematology and will appreicate any support no matter how big or small! Proceeds will go to improving patient care and wellbeing 🫰🏻🫰🏻🫰🏻🙏🏻🙏🏻 runmelbourne24.grassrootz.com/monashhealth/m…

A helpful article diving into the nuance of KMTAr AML and outcomes! -KRAS, TP53, or DNMT3A co-mutations with particularly poor outcomes nature.com/articles/s4137…

What better way 2 begin the academic year than 2 learn the “16+2” molecular subgroups of #MDSsm …. Never a better time to be a #hematopathologist 🎉 Going frm 3 genetically defined groups (multi TP53, SF3B1 and del 5q) of MDS to 16 👇🏼is a major advancement in our understanding

Thanks to those that contributed! 🙏 Great job by our team (some shown here) and a questionable pacer that pushed me to a PB! 🎉 Monash Health

Great to be part of an amazing Haem Team raising $$ for our Foundation ⁦Monash Health⁩ in RunMelbourne today. Thanks to all our supporters and donors ⁦Gareth Gregory⁩ ⁦Chyn C⁩

Happy to share novel risk signature for AML treated with Azacitidine and Venetoclax. These data derived from VIALE-A trial demonstrate mutations in four genes (TP53, FLT-3, KRAS, & NRAS) predict patient outcomes more definitively than ELN2022 or ELN 2017. doi.org/10.1182/blood.…

Congratulations to Dr Emma Leitinger and our anticoagulant stewardship team Monash Health as finalists in the 2024 Victorian Public Healthcare Awards. Making anticoagulants safer for our >2000 inpatients is no mean feat!

Abstracts accepted at the American Society of Hematology conference meeting ASH 2024 are considered the best out of thousands submitted worldwide and represent high impact and groundbreaking novel research in the field. Visit, tinyurl.com/4vepzupy for more info.

What do people usually have for breakfast during #ASH24?

Congratulations Chyn C - wonderful to see this work of Australasian Leukaemia & Lymphoma Group (ALLG) highlighted.

Congratulations to ALLG member Dr Chyn Chua who has just completed her podium presentation at ASH 2024 on the trial results of the ALLG AMLM25 INTERVENE, which aims to increase survival rates for people aged >60 with AML. Visit allg.org.au.

Congratulations Jad Othman on your abstract at #ASH24 examining outcomes in intensively treated AML with KMT2A rearrangements Intensified induction with FLAG-Ida improved MRD clearance and reduced relapse Molecular MRD after course 2 was a strong predictor of survival